ATE262915T1 - Zusammensetzungen zur verstärkung zytoprotektiver wirkung von polycyclischer phenolverbindungen durch synergistiche wechselwirkung von antioxidationsmitteln - Google Patents

Zusammensetzungen zur verstärkung zytoprotektiver wirkung von polycyclischer phenolverbindungen durch synergistiche wechselwirkung von antioxidationsmitteln

Info

Publication number
ATE262915T1
ATE262915T1 AT98903560T AT98903560T ATE262915T1 AT E262915 T1 ATE262915 T1 AT E262915T1 AT 98903560 T AT98903560 T AT 98903560T AT 98903560 T AT98903560 T AT 98903560T AT E262915 T1 ATE262915 T1 AT E262915T1
Authority
AT
Austria
Prior art keywords
compositions
antioxidants
enhancement
synergistic interaction
phenol compounds
Prior art date
Application number
AT98903560T
Other languages
English (en)
Inventor
James W Simpkins
Kelly E Gridley
Pattie S Green
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE262915T1 publication Critical patent/ATE262915T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT98903560T 1997-01-16 1998-01-16 Zusammensetzungen zur verstärkung zytoprotektiver wirkung von polycyclischer phenolverbindungen durch synergistiche wechselwirkung von antioxidationsmitteln ATE262915T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3553797P 1997-01-16 1997-01-16
US5351697P 1997-07-23 1997-07-23
US5810497P 1997-09-05 1997-09-05
PCT/US1998/000963 WO1998031381A1 (en) 1997-01-16 1998-01-16 Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants

Publications (1)

Publication Number Publication Date
ATE262915T1 true ATE262915T1 (de) 2004-04-15

Family

ID=27364864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903560T ATE262915T1 (de) 1997-01-16 1998-01-16 Zusammensetzungen zur verstärkung zytoprotektiver wirkung von polycyclischer phenolverbindungen durch synergistiche wechselwirkung von antioxidationsmitteln

Country Status (10)

Country Link
US (1) US5972923A (de)
EP (1) EP0977578B1 (de)
JP (1) JP2002501482A (de)
KR (1) KR100543151B1 (de)
AT (1) ATE262915T1 (de)
AU (1) AU719764B2 (de)
CA (1) CA2276146C (de)
DE (1) DE69822806T2 (de)
ES (1) ES2217538T3 (de)
WO (1) WO1998031381A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US6350739B1 (en) 1999-08-11 2002-02-26 University Of Florida Resarch Foundation, Inc. Methods of prevention and treatment of ischemic damage
WO2000028982A2 (en) 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
WO2002000619A2 (en) * 2000-06-27 2002-01-03 University Of Florida Research Foundation, Inc. Alkyl ether modified polycyclic compounds having a terminal phenol as cell protecting agents
WO2002013870A2 (en) * 2000-08-17 2002-02-21 Mitokor, Inc. Formulation for administering therapeutic lipophilic molecules
EP1834959B1 (de) 2000-11-03 2012-08-08 Washington University Tert-butyl-substituierte aromatische Steroide mit zytoprotektiver Wirkung
CA2427817C (en) * 2000-11-03 2009-04-14 Washington University Estrone-derivatives having cytoprotective activity
WO2002040032A2 (en) * 2000-11-17 2002-05-23 Washington University Cytoprotective estrogen derivatives
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
WO2002076206A2 (en) * 2001-03-23 2002-10-03 University Of Ottawa Methods and compositions for cryopreservation of dissociated primary animal cells
KR100523562B1 (ko) * 2001-10-29 2005-10-25 한국과학기술연구원 손바닥선인장 추출물 및 이로부터 분리된 화합물을함유하는 신경세포 보호용 조성물
AU2002359635A1 (en) * 2001-12-05 2003-06-17 Mitokor, Inc. Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
US6903220B2 (en) * 2002-05-15 2005-06-07 Genzyme Corporation Synthesis of chiral 2-alkyl amino acids
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
ATE357932T1 (de) * 2003-12-22 2007-04-15 Alcon Inc Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
US7304171B2 (en) * 2004-05-27 2007-12-04 Migenix Corp. Compounds and methods for cytoprotection
WO2008134220A1 (en) * 2007-05-01 2008-11-06 Vitrolife Ab Culture media for developmental cells containing elevated concentrations of lipoic acid
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
WO1996010401A1 (en) * 1994-10-04 1996-04-11 Emory University Methods for regulation of insulin-like growth factor i receptor

Also Published As

Publication number Publication date
AU719764B2 (en) 2000-05-18
AU6030698A (en) 1998-08-07
KR100543151B1 (ko) 2006-01-20
CA2276146A1 (en) 1998-07-23
JP2002501482A (ja) 2002-01-15
DE69822806D1 (de) 2004-05-06
CA2276146C (en) 2005-04-05
ES2217538T3 (es) 2004-11-01
WO1998031381A1 (en) 1998-07-23
EP0977578B1 (de) 2004-03-31
DE69822806T2 (de) 2005-03-10
US5972923A (en) 1999-10-26
EP0977578A1 (de) 2000-02-09
KR20000070183A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
DE69822806D1 (de) Zusammensetzungen zur verstärkung zytoprotektiver wirkung von polycyclischer phenolverbindungen durch synergistiche wechselwirkung von antioxidationsmitteln
GEP20104997B (en) Composition comprising anther2 antibodies
ATE411809T1 (de) Zusuammensetzungen zur behandlung von krebs mittels viren
ES2081870T3 (es) Composiciones polipropilenicas plasto-elasticas.
DK1144472T3 (da) Vandige reaktive spartelmasser (II)
ATE457970T1 (de) Zusammensetzungen zur beseitigung von unangenehmen gerüchen
ES2196630T3 (es) Isotiazolcarboxiamidas y su empleo para la proteccion de las plantas.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
ES2131322T3 (es) Derivados terpenicos polialcoxilos y composiciones que los contienen.
ATE135705T1 (de) Neue 2,6-dialkyl-4-silyl-phenole als antiatherosclerotische mittel und als antioxidantien
DE69529998D1 (de) Glp-1 zusammensetzungen mit verlängerter wirkdauer
DE69504953D1 (de) Verbesserung des remanenz eines geruchs durch verkapselung des riechstoffes
SE9404250L (sv) Affinitetsseparationsmetod
BG101892A (en) Sugar-modified cytostatics
ATE5960T1 (de) Metallchelate von 1,4-bis-(substituiertes amino-)-5,8-dihydroxy-anthrachinonen.
PT874625E (pt) Derivados de indano para composicoes antipsicoticas
WO2002064840A3 (en) Methods for identifying compounds that inhibit or reduce ptp1b expression
DE69935603D1 (de) Inhibitoren von autoantikörpern
ATE184604T1 (de) Neue 2-substituierte tricyclische derivate von indan-2-mercaptoacetylamid verwendbar als enkephalinase inhibitoren
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
FI924578A0 (fi) Korrosionsfoerhindrande, pigmenthaltig belaeggninskomposition
DE69606321T3 (de) Verwendung von 2-Ethylhexyl-alpha-cyano-beta, beta-diphenylacrylat zur Verbesserung der Lichtstabilität von p-Methylbenzylidencampher
ES2196559T3 (es) Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer.
DE69706775D1 (de) Durch einen Elekromagnet verriegelbarer Sicherheitsschalter
ES2164439T3 (es) Separacion de benceno de corrientes organicas utilizando ciclodextrinas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties